ACT-335827

ACT-335827
Clinical data
Routes of; administration	Oral
Drug class	Orexin 1 receptor antagonist
Identifiers
	IUPAC name (R)-2-((S)-1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-isopropyl-2-phenylacetamide;
PubChem CID	54765113;
ChemSpider	30774267;
ChEMBL	ChEMBL2413367;
Chemical and physical data
Formula	C31H38N2O5
Molar mass	518.654 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC(C(C2=C3)N(CCC2=CC(OC)=C3OC)(C(NC(C)C)=O)C4=CC=CC=C4)=CC=C1OC;
	InChI InChI=1S/C31H38N2O5/c1-20(2)32-31(34)30(22-10-8-7-9-11-22)33-15-14-23-18-28(37-5)29(38-6)19-24(23)25(33)16-21-12-13-26(35-3)27(17-21)36-4/h7-13,17-20,25,30H,14-16H2,1-6H3,(H,32,34)/t25-,30+/m0/s1; Key:HXHOBPVRRPCTLG-SETSBSEESA-N;

ACT-335827 is an orally available, selective orexin 1 receptor antagonist with anxiolytic effects in animals. Unlike other orexin receptor antagonists, ACT-335827 lacks sedative effects and was found to have no impact on sleep architecture in mice.^[1]^[2]

References

^ Steiner MA, Gatfield J, Brisbare-Roch C, Dietrich H, Treiber A, Jenck F, Boss C (June 2013). "Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist". ChemMedChem. 8 (6): 898–903. doi:10.1002/cmdc.201300003. PMID 23589487. S2CID 21644009.
^ Merlo Pich E, Melotto S (2014). "Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use". Frontiers in Neuroscience. 8: 26. doi:10.3389/fnins.2014.00026. PMC 3923148. PMID 24592206.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=ACT-335827
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[1] Steiner MA, Gatfield J, Brisbare-Roch C, Dietrich H, Treiber A, Jenck F, Boss C (June 2013). "Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist". ChemMedChem. 8 (6): 898–903. doi:10.1002/cmdc.201300003. PMID 23589487. S2CID 21644009.

[2] Merlo Pich E, Melotto S (2014). "Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use". Frontiers in Neuroscience. 8: 26. doi:10.3389/fnins.2014.00026. PMC 3923148. PMID 24592206.

[1]

[2]

v t e Orexin receptor modulators
OX₁	Agonists: Orexin (A, B) Antagonists: ACT-335827 ACT-462206 ACT-539313 Almorexant AZD-4041 C4X-3256 (INDV-2000) CR-5542 Daridorexant Filorexant GSK-649868 (SB-649868) JNJ-61393215 Lemborexant RTIOX-276 SB-334867 SB-408124 Suvorexant TCS-1102 Vornorexant (ORN-0829, TS-142) YZJ-1139
OX₂	Agonists: Danavorexton (TAK-925) Firazorexton Orexin (A, B) SB-668875 Suntinorexton TAK-861 TAK-994 Antagonists: ACT-335827 ACT-462206 Almorexant Daridorexant EMPA Filorexant GSK-649868 (SB-649868) JNJ-10397049 Lemborexant MK-1064 MK-3697 MK-8133 Seltorexant Suvorexant TCS-1102 TCS-OX2-29 Vornorexant (ORN-0829, TS-142) YZJ-1139

Clinical data

Routes of administration	Oral
Drug class	Orexin 1 receptor antagonist
Identifiers
IUPAC name (R)-2-((S)-1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-isopropyl-2-phenylacetamide
PubChem CID	54765113
ChemSpider	30774267
ChEMBL	ChEMBL2413367
Chemical and physical data
Formula	C₃₁H₃₈N₂O₅
Molar mass	518.654 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES COC1=CC(C(C2=C3)N(CCC2=CC(OC)=C3OC)(C(NC(C)C)=O)C4=CC=CC=C4)=CC=C1OC
InChI InChI=1S/C31H38N2O5/c1-20(2)32-31(34)30(22-10-8-7-9-11-22)33-15-14-23-18-28(37-5)29(38-6)19-24(23)25(33)16-21-12-13-26(35-3)27(17-21)36-4/h7-13,17-20,25,30H,14-16H2,1-6H3,(H,32,34)/t25-,30+/m0/s1 Key:HXHOBPVRRPCTLG-SETSBSEESA-N